Skip to main content

Table 1 Baseline characteristics of the calcitriol and placebo intervention groups

From: The efficacy of calcitriol treatment in non-alcoholic fatty liver patients with different genotypes of vitamin D receptor FokI polymorphism

variable Placebo group(n = 64) Calcitriol group(n = 64) p-value
Body weight, kg 83.3 ± 11.7 83.6 ± 13.1 0.88
BMI, kg/m2 29.3 ± 3.8 29.0 ± 4.7 0.67
WC, cm 101.8 ± 10.8 100.5 ± 8.8 0.44
HC, cm 107.2 ± 7.7 106.8 ± 9.2 0.78
FBS, mg/dl 94.2 ± 23.0 98.1 ± 38.3 0.49
Insulin, μIU/ml 10.8 ± 5.5 9.6 ± 4.8 0.17
Homa-IR 2.1 ± 0.9 2.0 ± 0.8 0.43
Quicki 0.33 ± 0.03 0.34 ± 0.03 0.54
HS Index 41.4 ± 5.8 41.4 ± 5.6 0.95
APRI index (IQR) 0.30 (0.22–0.38) 0.28 (0.23–0.37) 0.16
TC, mg/dl 188.0 ± 60.9 187.8 ± 46.5 0.98
TG (IQR),mg/dl 168.0 (121.5–210.5) 170.0 (134.0–236.0) 0.32
HDL cholesterol, mg/dl 41.4 ± 11.2 38.3 ± 7.9 0.07
LDL cholesterol, mg/dl 97.9 ± 27.5 96.6 ± 25.9 0.77
AST,IU 29.2 ± 15.6 27.1 ± 8.7 0.35
ALT (IQR), IU 45.5 (32.8–57.0) 23.0 (33.5–51.0) 0.53
GGT, IU 35.2 ± 17.8 37.2 ± 21.7 0.57
ALK, IU 200.2 ± 52.6 197.3 ± 54.9 0.76
Vitamin D, ng/ml 17.5 ± 7.7 19.1 ± 9.6 0.29
Hs-CRP (IQR), μg/ml 2.9 (1.1–5.5) 2.2 (1.1–4.8) 0.99
Leptin (IQR), ng/ml 11.6 (6.6–19.7) 9.9 (5.5–22.5) 0.30
Adiponectin (IQR), μg/ml 18.6 (13.6–28.2) 18.0 (10.8–24.4) 0.89
  1. Values are expressed as the mean ± SD or median (IQR). IQR interquartile range, BMI Body mass index, WC Waist circumference, HC Hip circumference, FBS Fasting blood glucose, Homa-IR Homeostatic Model Assessment for Insulin Resistance, HS index Hepatic steatosis index, APRI AST to Platelet Ratio Index, TC total cholesterol, TG Triglyceride, HDL-c High-density lipoproteins- cholesterol, LDL-c Low density lipoprotein- cholesterol, AST aspartate aminotransferase, ALT Alanine aminotransferase, GGT Gamma-glutamyl transferase, ALK Alkaline phosphatase, Hs-CRP High-sensitivity C-reactive protein